Document is current

Article History

Received: 14 December 2021

Accepted: 9 February 2022

First Online: 27 February 2022

Declarations

:

: Empire HF trial [] was designed, conducted and reported in accordance with a protocol in compliance with Good Clinical Practice and in accordance with the Declaration of Helsinki. All participants signed informed consent prior to inclusion. The Empire HF study protocol was approved by the relevant institutional review board (Danish National Committee on Health Research Ethics, number H-17010756).

: I, the undersigned, give my consent for the publication to be published in the Cardiovascular Diabetology Journal.

: MO reports grant from the Danish Heart Foundation, grants from The Steno Diabetes Center Odense (SDCO), Odense University Hospital Denmark, grants from A.P. Møller Foundation for the Advancement of Medical Science, Denmark related to present study, and personal fees from scientific advisory board from AstraZeneca, outside the submitted work. JJ reports grants from the Research Council at Herlev and Gentofte University Hospital, Denmark, grants from the Research and Innovation Foundation of the Department of Cardiology (FUHAS; formerly FUKAP), Herlev and Gentofte University Hospital, Denmark, grants from the A.P. Møller Foundation for the Advancement of Medical Science, Denmark, during the conduction of the study, and personal fees from scientific advisory board from AstraZeneca, outside the submitted work. CK reports personal fees from scientific advisory panels and speaker fees from Boehringer Ingelheim, Merck, Sharp & Dohme, AstraZeneca, Amgen, Novartis, Novo Nordisk, and Shire, outside the submitted work. KH, LV, JHL, and CFA have nothing to disclose. CT reports personal fees from scientific advisory panels and speaker fees from Orion Pharma and Bayer outside the submitted work. FG reports personal fees from Boehringer Ingelheim during the conduction of the study, personal fees from Novartis, grants and personal fees from Pfizer, and personal fees from Orion Pharma Abbott, Bayer, AstraZeneca, and Carmat, outside the submitted work. LK reports personal fees from speaker honorarium from Novartis, AstraZeneca, Novo Nordisk, and Boehringer Ingelheim, outside the submitted work. MS reports grants from The Capital Region of Denmark and grants from the Danish Heart Foundation, during the conduction of the study; personal fees and non-financial support from AstraZeneca, and personal fees from Novo Nordisk and Boehringer Ingelheim, outside the submitted work. JEM reports grant from Roche to perform GDF-15 analyses, research grant from Abiomed outside submitted work, and speaker honorarium from Abiomed, Novartis, Abbott, Boehringer Ingelheim and Orion Pharma, outside the submitted work.